Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Trulicity revenues up 20% in the quarter, driven by increased demand.

By: Contract Pharma

Contract Pharma Staff

Lilly

2Q Revenues: $5.5 billion (-2%)

2Q Earnings: $1.4 billion (+6%)

YTD Revenues: $11.4 billion (+6%)

YTD Earnings: $2.9 billion (-48%)

Comments: Trulicity revenue was $1.2 billion, up 20% in the quarter, driven by increased demand, partially offset by lower realized prices. Humalog revenue decreased 18% to $555.1 million. Revenue in the U.S. decreased 29 driven primarily by lower realized prices, reflecting a favorable Medicaid adjustment in 2Q19 and an unfavorable Managed Care adjustment in the quarter. Alimta revenue decreased 7% to $539.1 million, primarily driven by decreased demand in the U.S. Taltz revenue increased 12% to $395.2 million driven by increased demand, partially offset by lower realized prices. Humulin revenue decreased 3% to $313.6 million. U.S. revenue decreased 3%, to $214.3 million, driven by lower realized prices due to changes in segment mix. Basaglar revenue was flat at $290.4 million. Jardiance revenue was $262.0 million, up 13% compared with 2Q19, driven by increased demand. Forteo revenue decreased 30% to $252.7 million. U.S. revenue decreased 31%, driven by lower demand and lower realized prices. Cyramza revenue was $256.7 million, up 6%, primarily driven by higher realized prices and increased demand. Acquired in-process R&D expenses were $241.8 million in the quarter associated with upfront payments related to both a business development transaction with a preclinical stage company as well as transactions with AbCellera Biologics Inc., Evox Therapeutics, and Junshi Biosciences.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters